What the FDA labels say about taking them together
Ritonavir and ticagrelor
Ticagrelor's FDA label of May 7, 2026 names ritonavir in its drug interactions section; the ritonavir label PlainMeds reads does not name ticagrelor. The ticagrelor label: “Avoid use of strong inhibitors of CYP3A.”
Check it at the source: the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.); the ticagrelor FDA label on DailyMed (effective May 7, 2026, AstraZeneca Pharmaceuticals LP).
What does the ritonavir label say about ticagrelor?
Ritonavir's label (effective July 23, 2026) does not name ticagrelor in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed
What does the ticagrelor label say about ritonavir?
Ticagrelor label, drug interactionsAvoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (BRILINTA), AstraZeneca Pharmaceuticals LP, effective May 7, 2026 (SPL set f7b3f443-e83d-4bf2-0e96-023448fed9a8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ritonavir | Ticagrelor | |
|---|---|---|
| Labeled for | HIV | Heart attack and coronary artery disease, Stroke prevention |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.607 per tablet 100 mg tablet | $0.253 per tablet 90 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once